PD-1 (clone QR2)
Programmed Death 1 (PD-1, CD279) is a membrane protein that functions as a surface receptor for its ligands, PD-L1 and PD-L2. PD-1 is primarily expressed on activated T lymphocytes, B lymphocytes, and myeloid cells.
PD-1 acts as an immune checkpoint, playing a key role in immune regulation by inhibiting T-cell activation, which in turn reduces the risk of autoimmunity. However, some cancer cells exploit this mechanism to evade apoptosis by suppressing T-cell responses directed against them.
PD-1 (QR2) is a useful diagnostic marker for angioimmunoblastic T-cell lymphoma (AITL). Additionally, increased PD-1 expression has been associated with poor prognosis in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC).
Targeted PD-1 blockade therapies have shown promising results in the treatment of breast cancer, non-small cell lung cancer (NSCLC), and melanoma. [1-8]

